Health & Fitness
Wed, February 15, 2012Tue, February 14, 2012Mon, February 13, 2012Sun, February 12, 2012Fri, February 10, 2012Thu, February 9, 2012Wed, February 8, 2012Tue, February 7, 2012Mon, February 6, 2012Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
Published in Health and Fitness on Friday, February 10th 2012 at 3:44 GMT by Market Wire
Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on... -- ANAHEIM, Calif., Feb. 10, 2012 /PRNewswire/ --
Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
ANAHEIM, Calif., Feb. 10, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: [ QCOR ]) announced today that executive management will present at the Leerink Swann Global Healthcare Conference to be held on February 15-16, 2012 in New York. Steve Cartt, Executive Vice President and Chief Business Officer, is scheduled to present an overview of the Company on Thursday, February 16, 2012 at 2:30 p.m. ET.
A live webcast and subsequent archived replay of the presentation will be accessible at [ http://ir.questcor.com/events.cfm ]. The replay will be available for 90 days after the event.
About Questcor
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies. For more information, please visit [ www.questcor.com ].
SOURCE Questcor Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.questcor.com ]
